467 related articles for article (PubMed ID: 19819923)
1. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
[TBL] [Abstract][Full Text] [Related]
2. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
Molina A; Krishnan A; Fung H; Flinn IW; Inwards D; Winter JN; Nademanee A
Curr Stem Cell Res Ther; 2007 Sep; 2(3):239-48. PubMed ID: 18220907
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Bethge WA; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
Bone Marrow Transplant; 2012 Nov; 47(11):1397-402. PubMed ID: 22504934
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Bethge WA; Lange T; Meisner C; von Harsdorf S; Bornhaeuser M; Federmann B; Stadler M; Uharek L; Stelljes M; Knop S; Wulf G; Trenschel R; Vucinic V; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
Blood; 2010 Sep; 116(10):1795-802. PubMed ID: 20530284
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Exp Hematol; 2007 Apr; 35(4):534-40. PubMed ID: 17379063
[TBL] [Abstract][Full Text] [Related]
10. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
11. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
12. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
[TBL] [Abstract][Full Text] [Related]
13. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L; Guidetti A; Tarella C; Magni M; Matteucci P; Seregni E; Chiesa C; Bombardieri E; Di Nicola M; Carlo-Stella C; Gianni AM
J Clin Oncol; 2008 Nov; 26(32):5175-82. PubMed ID: 18854569
[TBL] [Abstract][Full Text] [Related]
14. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
15. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A; Forman SJ
Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
[TBL] [Abstract][Full Text] [Related]
16. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
Winter JN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146
[TBL] [Abstract][Full Text] [Related]
17. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Bone Marrow Transplant; 2008 Feb; 41(4):355-61. PubMed ID: 18026153
[TBL] [Abstract][Full Text] [Related]
18. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
[TBL] [Abstract][Full Text] [Related]
19. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
[TBL] [Abstract][Full Text] [Related]
20. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.
Gisselbrecht C; Bethge W; Duarte RF; Gianni AM; Glass B; Haioun C; Martinelli G; Nagler A; Pettengell R; Sureda A; Tilly H; Wilson K
Bone Marrow Transplant; 2007 Dec; 40(11):1007-17. PubMed ID: 17922042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
